January 2002
Royal Society of Medicine: Medicines;2002, p297
Reference Entry
This article provides information on the drug imatinib. It is a recently introduced protein-tyrosine kinase inhibitor cytotoxic drug, which is used as an anticancer treatment for myeloid leukemia. It works by interference with the action of an abnormal form of an enzyme in the body that can cause this condition. Administration is oral. The drug may cause vomiting, nausea, diarrhoea, muscle pain, oedema and headache.


Related Articles

  • Imatinib en première ligne dans la LMC en 2012: un traitement « dépassé » ? Giraudier, S. // Oncologie;Oct2012, Vol. 14 Issue 10/11, p579 

    The initial management of chronic myeloid leukemia (CML) in chronic phase is now based solely on treatment with tyrosine-kinase inhibitor (TKI). The development of second generation inhibitors and their use in first-line treatment raises the issue of choice of TKI in the first prescription....

  • Imatinib.  // Reactions Weekly;1/20/2007, Issue 1135, p18 

    The article discusses a case report on the side effects of imatinib. It references a study by J. C. Pascual et al, published in the December 2006 issue of the "International Journal of Dermatology." It presents two cases of old women who developed lichenoid eruptions during treatment with...

  • Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy. Pytel, Dariusz; Sliwinski, Tomasz; Poplawski, Tomasz; Ferriola, Deborah; Majsterek, Ireneusz // Anti-Cancer Agents in Medicinal Chemistry;2009, Vol. 9 Issue 1, p66 

    Tyrosine kinases (TKs) are attractive targets for cancer therapy, as quite often their abnormal signaling has been linked with tumor development and growth. Constitutive activated TKs stimulate multiple signaling pathways responsible for DNA repair, apoptosis, and cell proliferation. During the...

  • Targeted therapies for CML: practical considerations and comparisons. Blamble, Debbie; Michaud, Laura Boenhnke // Hem/Onc Today;8/10/2008, Vol. 9 Issue 14, p14 

    The article discusses other targeted therapies that have been approved for Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML), since the approval of imatinib. Among them are two new tyrosine kinase (TK) inhibitors, dasatinib and nilotinib. A comparison between dasatinib, imatinib...

  • Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia. O'Brien, S. G.; Meinhardt, P.; Bond, E.; Beck, J.; Peng, B.; Dutreix, C.; Mehring, G.; milosavljev, S.; Huber, C.; Capdeville, R.; Fischer, T. // British Journal of Cancer;11/17/2003, Vol. 89 Issue 10, p1855 

    The inhibition by imatinib of the cytochrome P450 3A4 isoenzyme may reduce the CYP3A4-mediated metabolic clearance of clinically important coadministered drugs. The main purpose of this study was to evaluate the effect of the coadministration of imatinib on the pharmacokinetics of simvastatin, a...

  • START-R, START-C: Dasatinib in the treatment of CML-CP.  // Hem/Onc Today;4/10/2008, Vol. 9 Issue 6, p9 

    The article discusses the outcomes of the START-R and START-C studies involving patients with chronic phase chronic myeloid leukemia who are resistant to standard dose imatinib. It references a study by H. M. Kantajian and colleagues, and a study by R. M. Stone and colleagues, both presented at...

  • Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients. Breccia, Massimo; Alimena, Giuliana // BioDrugs;2011, Vol. 25 Issue 3, p147 

    Dasatinib is an oral dual tyrosine kinase inhibitor active against ABL1 and SRC family kinases. The US FDA approved it for the treatment of chronic myeloid leukemia (CML) patients in chronic, accelerated, or blastic phase with resistance or intolerance to imatinib therapy. Dasatinib is also...

  • Hydroxycarbamide/imatinib.  // Reactions Weekly;12/15/2007, Issue 1182, p19 

    The article describes the case of four patients who developed myelosuppression while receiving imatinib and hydroxycarbamide. They receive imatinib and hydoxycarbamide in 4-week cycles for glioblastoma. Treatments received by the patients include packed red blood cell and platelet transfusions,...

  • Omacetaxine as an Anticancer Therapeutic: What is Old is New Again. Wetzler, Meir; Segal, David // Current Pharmaceutical Design;1/1/2011, Vol. 17 Issue 1, p59 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics